On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Genmab Poised to Triple Japan Staff for Stand-Alone Biz, First Up Is ADC for Cervical Cancer
January 22, 2021
-
BUSINESS Moderna’s COVID-19 Shot Enters Clinical Trial in Japan: Takeda
January 21, 2021
-
REGULATORY Kobayashi Kako Submits Report on Drug Mix-Up, Could Face Administrative Penalty in 1st Half of February
January 21, 2021
-
REGULATORY Japan, Pfizer Finalize COVID-19 Vaccine Deal, Agree on Supply of 144 Million Doses
January 21, 2021
-
BUSINESS Will Cymbalta, E Keppra Face Generic Competition This Year? Vesicare, Aloxi Too?
January 20, 2021
-
REGULATORY MHLW Eyes 1st Revision of Drug Industry Vision in 8 Years as Off-Year Re-Pricing Takes Shape: Official
January 19, 2021
-
REGULATORY Kono Responsible for Logistics Part of COVID-19 Vaccine Rollout
January 19, 2021
-
REGULATORY Kono Tapped to Oversee COVID-19 Vaccine Rollout
January 19, 2021
-
BUSINESS BIKEN to Stop Shipment of Japanese Encephalitis Vaccine on Bacterial Contamination
January 18, 2021
-
REGULATORY Special Mitigation Margin for COVID-19 Up for Debate towards FY2022 Drug Price Revision: MHLW Bureau Chief
January 15, 2021
-
BUSINESS Nichi-Iko Announces Yet Another Recall, 38 Products Added to Bring Total to 75
January 14, 2021
-
ORGANIZATION Generic Use Targets Should Be Set by City/Ward in Major Prefectures: Professor
January 14, 2021
-
REGULATORY MHLW to Run Fresh Survey on Drug Makers’ Responses to Promotion Guidelines
January 13, 2021
-
BUSINESS Kobayashi Kako Expected to Face Administrative Penalty This Fiscal Year, Biz Suspension Likely
January 12, 2021
-
BUSINESS Drug Makers, Wholesalers Boost WFH as Japan Declares Second Emergency
January 12, 2021
-
COMMENTARY Potential Reimbursement Challenges of Aducanumab Could Usher in Health Insurance Overhaul in Japan
January 8, 2021
-
REGULATORY PMDA Updates Veklury Label to Allow Its Use in Moderate COVID-19
January 8, 2021
-
ORGANIZATION Japan Pharma Lobbies Shifting to Manabe/Okada Leadership? Their Abilities Will Be Tested as Industry Grapples with Thorny Issues
January 7, 2021
-
ACADEMIA Japan Reports Mother-to-Infant Cervical Tumor Transmission via Amniotic Fluids
January 7, 2021
-
BUSINESS Drug Makers, Wholesalers Brace for Second Emergency Declaration in Japan
January 6, 2021
ページ
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…